Humate p dosing

by M Franchini 2024 Cited by 11Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with

HUMATE-P is for intravenous use only. HUMATE-P is available as a lyophilized powder in single-dose vials that contain the labeled amount of VWF:RCo and FVIII activity expressed in IU. The average ratio of VWF:RCo to FVIII is 2.4:1. Do not refrigerate HUMATE-P after reconstitution. Administer within 3 hours after reconstitution.

Detailed Humate-P dosage information Precautions while using Humate-P It is very important that your doctor check you closely while you or your child are receiving this medicine to make sure it is working properly.

Humate P, Alphanate, Wilate and Koate HP are commercially available for Products with higher VWF:RCo/FVIII ratios allow for more frequent dosing of

Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/HUMATE-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2024;87(2): . Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA; HUMATE-P Study Group.

The recommended dosing of Haemate P/Humate-P is based preferentially on VWF:RCo activity, which is approximately twice that of FVIII:C (2.4:1). Haemate P/Humate-P has been shown to be safe; no serious adverse events or cases of thrombosis have been observed in clinical trials and no documented cases of viral transmission in nearly three decades

(Humate-P). Mice required pretreatment with a PAF (platelet Double-blind study of the safety of clopidogrel with and without a loading dose

Haemate P/Humate-P, the first plasma-derived von Willebrand factor (VWF)/ Guidelines for dosing have been developed; optimal dosing depends on the

Humate-P: Note: Dosing for treatment of bleeding episodes in. VWD versus Hemophilia A is different. Hemophilia A (dose is expressed in units